Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 5/20 | 0.35 |
| ▸ | PKLR | P30613 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10652711 | 0.83 | MEN1 (0.52) | HTR6NR4A1CA1CA2CA9 | |
| SCHEMBL543840 | 0.81 | TUBB4A (0.44) | NR4A1METCDK9CA1CA2 | |
| SCHEMBL11089561 | 0.78 | GPR17 (0.43) | HTR6NR4A1CA1CA2CA9 | |
| SCHEMBL10656325 | 0.76 | SOS1 (0.46) | HTR6NR4A1CA1CA2CA9 | |
| SCHEMBL30626039 | 0.75 | CA1 (0.47) | HTR6CA1CA2CA9PKM | |
| SCHEMBL10652647 | 0.75 | CA12 (0.47) | NR4A1CA1CA2CA9PKM | |
| SCHEMBL10651300 | 0.75 | ALDH1A1 (0.49) | NR4A1CA1CA2CA9CA12 | |
| SCHEMBL11850296 | 0.75 | TUBB4A (0.40) | NR4A1METCDK9CA1CA2 | |
| SCHEMBL11841874 | 0.75 | TDP1 (0.56) | NR4A1CA1CA2CA9CA12 | |
| SCHEMBL543995 | 0.74 | CA2 (0.57) | CA1CA2PKMKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110571-B2 | Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents | AVENTIS PHARMA S.A. (FR) | 2012-02-07 | — | — | US | disclosed |
| CN-101273019-A | Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as C-Met inhibitors | AVENTIS PHARMA SA (FR) | 2008-09-24 | — | — | CN | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | HTR6 600/4885NR4A1 2757/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.